Tongxinluo Activates PI3K/AKT Signaling Pathway to Inhibit Endothelial Mesenchymal Transition and Attenuate Myocardial Fibrosis after Ischemia-Reperfusion in Mice

Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and clinical applications

“…The research results show that TXL weakens MF after AMI by inhibiting EndMT and activating the NRG-1/ErbB-PI3K/AKT signaling cascade. In order to further explore the potential role of TXL in reducing myocardial fibrosis after myocardial ischemia-reperfusion injury (MIRI) in mice, Wei, Y. R. et al [ 128 ] established a MIRI mouse model using left anterior descending coronary artery ligation, with a ligation time of 45 min. On the second day after modeling, TXL and benazepril (BNPL) were administered by gavage for 4 consecutive weeks.…”